BFIC
REGN icon

Bedell Frazier Investment Counselling’s Regeneron Pharmaceuticals REGN Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.33M Buy
6,900
+28
+0.4% +$21.4K 1.08% 30
2025
Q4 		$5.3M Sell
6,872
-21
-0.3% -$14.3K 1.02% 35
2025
Q3 		$3.88M Sell
6,893
-522
-7% -$295K 0.8% 37
2025
Q2 		$3.89M Sell
7,415
-406
-5% -$227K 0.98% 33
2025
Q1 		$4.96M Buy
7,821
+2,916
+59% +$2.01M 1.26% 26
2024
Q4 		$3.49M Buy
4,905
+92
+2% +$77.2K 0.87% 36
2024
Q3 		$5.06M Sell
4,813
-41
-0.8% -$45.6K 1.21% 30
2024
Q2 		$5.1M Sell
4,854
-1,960
-29% -$1.9M 1.23% 32
2024
Q1 		$6.56M Sell
6,814
-60
-0.9% -$57.1K 1.64% 23
2023
Q4 		$6.04M Sell
6,874
-63
-0.9% -$51.9K 1.66% 23
2023
Q3 		$5.71M Sell
6,937
-3,176
-31% -$2.5M 1.71% 23
2023
Q2 		$7.27M Sell
10,113
-447
-4% -$345K 2.13% 17
2023
Q1 		$8.68M Sell
10,560
-205
-2% -$155K 2.54% 13
2022
Q4 		$7.77M Sell
10,765
-304
-3% -$224K 2.03% 16
2022
Q3 		$7.63M Sell
11,069
-60
-0.5% -$37.8K 2.14% 16
2022
Q2 		$6.58M Sell
11,129
-80
-0.7% -$52K 2.02% 20
2022
Q1 		$7.83M Sell
11,209
-124
-1% -$78.4K 1.98% 17
2021
Q4 		$7.16M Buy
11,333
+68
+0.6% +$41.8K 1.74% 20
2021
Q3 		$6.82M Sell
11,265
-2,923
-21% -$1.81M 1.87% 20
2021
Q2 		$7.92M Buy
14,188
+280
+2% +$142K 2.01% 16
2021
Q1 		$6.58M Buy
13,908
+5,714
+70% +$2.78M 1.86% 23
2020
Q4 		$3.96M Buy
8,194
+3,993
+95% +$2.16M 1.21% 34
2020
Q3 		$2.35M Sell
4,201
-88
-2% -$53.4K 0.84% 38
2020
Q2 		$2.67M Sell
4,289
-25
-0.6% -$14.2K 1.08% 30
2020
Q1 		$2.11M Buy
+4,314
New +$1.78M 0.99% 31

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bedell Frazier Investment Counselling's REGN Position: Q1 2026 in Review

Bedell Frazier Investment Counselling increased its Regeneron Pharmaceuticals (REGN) stake by 0.41% in Q1 2026, buying an estimated $21.4K and bringing the position to 6,900 shares worth $5.33M. The position accounts for 1.08% of the portfolio, ranked #30.

Bedell Frazier Investment Counselling first reported a position in REGN in Q1 2020 and has held it in 25 quarters since. The position peaked at $8.68M in Q1 2023. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Bedell Frazier Investment Counselling held 6,900 shares of Regeneron Pharmaceuticals worth $5.33M as of Q1 2026.
  • Bedell Frazier Investment Counselling bought 28 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $21.4K.
  • Regeneron Pharmaceuticals made up 1.08% of Bedell Frazier Investment Counselling's portfolio in Q1 2026, its #30 holding.
  • Bedell Frazier Investment Counselling first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Bedell Frazier Investment Counselling's Regeneron Pharmaceuticals position peaked at $8.68M in Q1 2023.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bedell Frazier Investment Counselling's 13F filing for Q1 2026, filed 15 May 2026.